Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Accreditations And Approvals
    • Good Laboratory Practice
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s, Guide Book and Forms for Shareholders
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Media » Press Releases
  • Media
    • Press Releases
    • Presentations

Press Releases

  • 10-Dec-2021
    SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting
  • 08-Dec-2021
    SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma
  • 03-Dec-2021
    SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target
  • 26-Nov-2021
    SPARC to Provide Update on Clinical Programs and R&D Pipeline
  • 14-May-2021
    SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension
  • 14-Oct-2020
    SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery
  • 22-Sep-2020
    SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics
  • 19-Aug-2020
    SPARC to Provide Update on R&D Pipeline
  • 28-May-2020
    SPARC enters into a worldwide license agreement for SCD-044 with Sun Pharma
  • 13-Feb-2020
    SPARC to Provide Update on TaclantisTM NDA

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page ››
  • Last page Last »

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits